Last edition
News about "chronic aging-related conditions"
Longeveron's Laromestrocel Trial Misses Primary Endpoint in HLHS
Longeveron’s investigational stem cell therapy laromestrocel did not meet the primary efficacy endpoint in the Phase 2b ELPIS 2 trial evaluating infants with hypoplastic left heart syndrome.
Chronic Aging-related Conditions | 21/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members